Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study
Recruiting
Phase 4
Interventional Study
Overactive Bladder (OAB)
Overactive Bladder Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Female
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 480 (estimated)
- Sponsor
- Mansoura University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage.
Women who join the study will be randomly placed into one of two groups:
One group will take tadalafil (5 mg), a medicine taken once a day.
The other group will take solifenacin (5 mg), a common treatment fo…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* OAB symptoms persisting for ≥3 months
* OAB Symptom Score (OABSS) \> 5 and urgency sub-score of OABSS ≥ 2
* Ability and willingness to provide informed consent.
Exclusion Criteria:
* Active urinary tract infection.
* Stress urinary incontinence (SUI) as primary diagnosis, or…
Contacts